Fair Value Calculator Fair Value Calculator
EN DE

IVX (IVX) Fair Value & Analysis

Healthcare · Market cap A$4.7M

I IVX IVX · AU
PriceA$0.0400
Fair ValueA$0.1120
Upside+180.0%
Quality28/100
Watch IVX for free — get notified when fair value or trend changes. Watch for free
Evidence: Low Range A$0.0640 – A$0.1760

Fair value as of: Jun 26, 2026

From 3 valuation models · updated 6 days ago

Fair value updated Jun 26, 2026 — revised from A$0.3800 to A$0.1120 (−70.5%) since Jun 24, 2026. Share price −30.4% over the past month.

Price vs Fair Value (12 months)

A$0.1813 A$0.0400 Fair Value A$0.1120 Jun 2025 Jul 2026

12‑month range A$0.0400 – A$0.1813 · fair‑value band A$0.0640 – A$0.1760 · the A$0.0400 price screens below the A$0.1120 fair value. As of Jun 26, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

IVX (IVX) currently trades at A$0.0400, while our model-based Fair Value estimate is A$0.1120 — implying the stock looks roughly 180.0% undervalued today. We read business quality at 28/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

Trailing-twelve-month revenue stands at A$3.0K. Fundamentals as of Jun 26, 2026

Key figures & financial health

Revenue (TTM) A$3.0K
Revenue growth (YoY) -99.8%
Return on equity -112%
Free cash flow −A$3.0M FY2025
EPS (TTM) A$-0.1400
Net cash A$850K FY2025

Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

IVX reported revenue of A$0 in FY2025 versus A$2.3M in FY2021. Reported net income was −A$8.8M in FY2025.

Revenue
FY21 A$2.3M
FY22 A$3.3M
FY23 A$4.1M
FY24 A$3.7M
FY25 A$0
Net income
FY21 −A$1.5M
FY22 −A$2.2M
FY23 −A$1.6M
FY24 −A$5.6M
FY25 −A$8.8M

Is IVX fairly valued? → Check now

Similar stocks

6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).

Stock Price Fair Value vs Fair Value
1276 1276 HK$57.85 HK$29.84 -48%
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥47.01 ¥26.59 -43%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,782 ₹915.92 -49%
Zoetis Inc Z1TS34 R$26.19 R$26.01 -1%
Hansoh Pharmaceutical Group 3692 HK$29.58 HK$18.75 -37%
Divi's Laboratories Limited DIVISLAB ₹6,788 ₹2,035 -70%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is IVX (IVX) undervalued?
As of Jun 26, 2026, our model estimates a fair value of A$0.1120 versus a price of A$0.0400 — about +180% (undervalued). Model-based estimate, not financial advice.
What is the fair value of IVX?
Our model-based fair value for IVX is A$0.1120 (as of Jun 26, 2026), built from audited fundamentals. The current price is A$0.0400.
What is the quality score of IVX?
IVX has a Quality Score of 28/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of IVX (IVX)?
IVX reported trailing-twelve-month revenue of about A$3.0K (latest available figure, as of Jun 26, 2026).
What is the net profit margin of IVX?
The net profit margin of IVX is about 0.0%, meaning it keeps roughly 0.0% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.